<DOC>
	<DOCNO>NCT02213094</DOCNO>
	<brief_summary>This open label dose escalation safety study vitamin B3-amide dietary supplementation pregnant woman hypertensive complication pregnancy . The investigator enroll 5 pregnant woman 24-36 week ' gestation diagnosis hypertensive complication pregnancy . If woman anticipate remain undelivered 48 hour diagnosis receive vitamin B3-amide , 500 mg/day single daily dose , continue two week delivery , ever occur first . Maternal blood collect baseline 2 time per week measure maternal LFTs study marker ( nicotinamide metabolite , sFlt-1-Soluble fms-like tyrosine kinase-1 PlGF ) . The objective dose escalation safety study determine safety vitamin B3 amide dietary supplementation expectant management hypertensive complication pregnancy .</brief_summary>
	<brief_title>Nicotinamide Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Hypertension , Pregnancy-Induced</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1 . Maternal age 1845 year 2 . Informed write consent 3 . Preeclampsia new onset hypertension 2436 week ' gestation 1 . Hypertensive complication pregnancy define new onset systolic BP &gt; 140 mm Hg and/or diastolic BP &gt; 90 mm Hg two occasion 6 hour apart ; OR &gt; 300 mg proteinuria 24 hour urine collection OR urine P/C ratio &gt; 0.3 ; 2 . Dating criterion base menstrual dating confirm first second trimester ultrasound OR second trimester ultrasound menstrual dating unavailable ; 3 . Deemed clinically stable primary clinician candidate expectant management ( delayed delivery ) ; 4 . Maternal liver function test &lt; 3x ULN 5 . Maternal platelet count &gt; 100,000 mm3 6 . Fetal wellbeing establish estimate fetal weight &gt; 5th % tile ; normal amniotic fluid volume ( MVP &gt; 2 cm ) ; normal Umbilical Artery Dopplers ; AND reactive NST ( nonstress test ) BPP ( biophysical profile ) &gt; 6 7 . Plan expectant management delivery 8 . Delivery anticipate within first 48 hour 1 . Preeclampsia &lt; 24 &gt; 36 week ' gestation ; 2 . Suspected fetal structural chromosomal abnormality ; 3 . Preexisting renal disease ( creatinine &gt; 1.5 mg/dL ) 4 . Preexisting vascular disease ( systemic lupus ; cardiac disease ; ) 5 . Plan delivery within 48 hour 6 . Any preexist medical condition would increase risk liver toxicity ( e.g . hepatitis B C ; HIV ) 7 . Evidence cerebral dysfunction ( seizure ; cerebral edema CT/MRI ; headache unresolved oral analgesic ) 8 . Pulmonary edema 9 . HELLP ( hemolysis , elevate liver enzyme , low platelet syndrome ) 10 . Evidence liver dysfunction ( LFTs &gt; 3x ULN ) 11 . Thrombocytopenia ( platelet &lt; 100,000 mm3 ) 12 . Evidence fetal compromise : EFW ( estimate fetal weight ) &lt; 5th percentile ; BPP &lt; 6 ; absent reverse diastolic UA blood flow ; oligohydramnios ( MVP &lt; 2 cm ) 13 . Placental abruption define unexplained vaginal bleeding 14 . Preterm labor define regular contraction cervical change 15 . Any condition deem investigator risk mother fetus completion study 16 . Any condition deem investigator require delivery within 48 hour</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>preeclampsia</keyword>
	<keyword>pregnancy-induced hypertension</keyword>
	<keyword>nicotinamide</keyword>
</DOC>